New Era in Vitiligo and Atopic Dermatitis Treatment with Opzelura

Abstract

In recent years, topical Janus kinase (JAK) inhibitors have emerged as promising novel agents for the treatment of inflammatory skin diseases such as vitiligo and atopic dermatitis. The FDA-approved Opzelura® (ruxolitinib 1.5% cream) has demonstrated significant efficacy and safety in clinical trials. Phase 3 studies in vitiligo patients showed marked repigmentation, while atopic dermatitis trials reported substantial symptom reduction and improved quality of life. These recent findings from Europe and the United States reinforce the therapeutic role of ruxolitinib cream in dermatology. However, the lack of regulatory approval in Turkey restricts patient access to this innovative treatment. This letter highlights the urgent need for Opzelura’s approval in Turkey, emphasizing its potential as a vital option for treatment-resistant patients and its contribution to advancing dermatological practice